Japanese subsidiary of the Sosei Group, Sosei Co, has commenced a Phase III study of an antifungal agent, SO-1105, for the treatment of oropharyngeal candidiasis caused by Candida species.
The open-label, randomised, multiple centre study with parallel-group design is designed to evaluate the efficacy and safety of SO-1105, with open active comparator miconazole gel.
Go deeper with GlobalData
Sosei Group CEO Shinichi Tamura said; "This is an important step forward in development of SO-1105. With its once-daily mucoadhesive administration, SO-1105 is expected to improve compliance and patients’ quality of life."
The company believes that the antifungal agent has the potential to become the first long-acting, sustained-release treatment available in the form of a tablet.
France-based BioAlliance Pharma originally developed SO-1105, which is administered as a muco-adhesive buccal tablet against oropharyngeal candidiasis in immunocompromised patients.
Since obtaining its first marketing authorisation in France in October 2006, SO-1105 has been registered across 24 European countries, in South Korea and in the US, under the trade names Loramyc and Oravig.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
